Literature DB >> 16002302

Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer.

Michael R Freeman1, Bekir Cinar, Michael L Lu.   

Abstract

Recent evidence indicates that nuclear receptors for steroid hormones can signal by nongenomic mechanisms that operate independently of their transcription function. These signal-transduction processes occur within seconds to minutes after initiation with agonist and involve interactions between nuclear receptors and other signaling proteins in the cytoplasm and at membrane surfaces. This review provides an overview of published information on possible nongenomic activities of the androgen receptor (AR) and other nuclear receptors, focusing on the potential involvement of these processes in prostate cancer. We discuss the hypothesis that the cholesterol-rich lipid-raft compartment(s) of cancer-cell membranes might provide privileged sites for nongenomic signals mediated by the AR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002302     DOI: 10.1016/j.tem.2005.06.002

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  29 in total

1.  Integrins regulate microtubule nucleating activity of centrosome through mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling.

Authors:  Diane Colello; Shomita Mathew; Rachel Ward; Kevin Pumiglia; Susan E LaFlamme
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

2.  Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.

Authors:  Wen-Chin Huang; Xiangyan Li; Jian Liu; Jentai Lin; Leland W K Chung
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

3.  Statin use and fatal prostate cancer: a matched case-control study.

Authors:  Stephen W Marcella; Alice David; Pamela A Ohman-Strickland; Jeffery Carson; George G Rhoads
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

4.  Redefining hormone resistance in prostate cancer.

Authors:  Christopher J Hoimes; W Kevin Kelly
Journal:  Ther Adv Med Oncol       Date:  2010-03-01       Impact factor: 8.168

5.  Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.

Authors:  Robert J Hamilton; Lionel L Banez; William J Aronson; Martha K Terris; Elizabeth A Platz; Christopher J Kane; Joseph C Presti; Christopher L Amling; Stephen J Freedland
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

Review 6.  Rapid signaling by steroid receptors.

Authors:  Ellis R Levin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-09-10       Impact factor: 3.619

7.  Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer.

Authors:  Renee E Vickman; Scott A Crist; Kevin Kerian; Livia Eberlin; R Graham Cooks; Grant N Burcham; Kimberly K Buhman; Chang-Deng Hu; Andrew D Mesecar; Liang Cheng; Timothy L Ratliff
Journal:  Mol Cancer Res       Date:  2016-06-24       Impact factor: 5.852

Review 8.  Rationale for statins in the chemoprevention of prostate cancer.

Authors:  Robert J Hamilton; Stephen J Freedland
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

9.  Plasma membrane cholesterol content affects nitric oxide diffusion dynamics and signaling.

Authors:  Shane Miersch; Michael Graham Espey; Ruchi Chaube; Arzu Akarca; Rodney Tweten; Sirinart Ananvoranich; Bulent Mutus
Journal:  J Biol Chem       Date:  2008-04-29       Impact factor: 5.157

10.  Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo.

Authors:  Shuchen Gu; Natalia Papadopoulou; Eva-Maria Gehring; Omaima Nasir; Konstantinos Dimas; Shefalee K Bhavsar; Michael Föller; Konstantinos Alevizopoulos; Florian Lang; Christos Stournaras
Journal:  Mol Cancer       Date:  2009-12-01       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.